Page 155 - Read Online

Spiliopoulou et al. Cancer Drug Resist 2024;7:2 https://dx.doi.org/10.20517/cdr.2023.46 Page 23

comparison. J Pharm Biomed Anal 2019;162:249-56. DOI PubMed
135. Shin N, Stubbs M, Koblish H, et al. Parsaclisib is a next-generation phosphoinositide 3-kinase δ inhibitor with reduced hepatotoxicity
and potent antitumor and immunomodulatory activities in models of B-cell malignancy. J Pharmacol Exp Ther 2020;374:211-22.
DOI
136. Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert
Opin Investig Drugs 2017;26:625-32. DOI PubMed PMC
137. Gadkar K, Friedrich C, Hurez V, et al. Quantitative systems pharmacology model-based investigation of adverse gastrointestinal
events associated with prolonged treatment with PI3-kinase inhibitors. CPT Pharmacometrics Syst Pharmacol 2022;11:616-27. DOI
PubMed PMC
+
138. Sharma A, Subudhi SK, Blando J, et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3 regulatory T cells (Tregs) in human
cancers. Clin Cancer Res 2019;25:1233-8. DOI PubMed PMC
139. Retseck J, Nasr A, Lin Y, et al. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses
in patients with melanoma. J Transl Med 2018;16:184. DOI PubMed PMC
140. Patel TH, Brewer JR, Fan J, et al. FDA approval summary: tremelimumab in combination with durvalumab for the treatment of
patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2023. DOI
141. Lowther DE, Goods BA, Lucca LE, et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight
2016;1:e85935. DOI PubMed PMC
142. Hong DS, Rixe O, Chiu VK, et al. Mogamulizumab in combination with nivolumab in a phase I/II study of patients with locally
advanced or metastatic solid tumors. Clin Cancer Res 2022;28:479-88. DOI PubMed PMC
143. Kidani Y, Nogami W, Yasumizu Y, et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes
potent tumor immunity with long-lasting memory. Proc Natl Acad Sci U S A 2022;119:e2114282119. DOI PubMed PMC
144. Weaver JD, Stack EC, Buggé JA, et al. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of
tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Oncoimmunology 2022;11:2141007.
DOI PubMed PMC
145. Solomon I, Amann M, Goubier A, et al. CD25-T -depleting antibodies preserving IL-2 signaling on effector T cells enhance effector
reg
activation and antitumor immunity. Nat Cancer 2020;1:1153-66. DOI PubMed PMC
146. Wyant T, Frentzas S, Ahern E, et al. Abstract C033: preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation
trial in patients with advanced solid tumors. Molecular Cancer Therapeutics 2023;22:C033. DOI
147. Cole CB, Morelli MP, Fantini M, et al. Correction: first-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal
antibody NEO-201 in treatment-refractory solid tumors. J Exp Clin Cancer Res 2023;42:102. DOI PubMed PMC
148. Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res
2012;72:3439-44. DOI PubMed PMC
+ +
149. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 CD25 regulatory T cells
and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8. DOI
150. Scurr M, Pembroke T, Bloom A, et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with
survival in metastatic colorectal cancer. Clin Cancer Res 2017;23:6771-80. DOI PubMed PMC
151. Roselli M, Cereda V, di Bari MG, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T
cells. Oncoimmunology 2013;2:e27025. DOI PubMed PMC
152. Revenko A, Carnevalli LS, Sinclair C, et al. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to
relieve immunosuppression in cancer. J Immunother Cancer 2022;10:e003892. DOI PubMed PMC
153. Eschweiler S, Ramírez-Suástegui C, Li Y, et al. Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. Nature
2022;605:741-6. DOI PubMed PMC
154. Tarantelli C, Argnani L, Zinzani PL, Bertoni F. PI3Kδ inhibitors as immunomodulatory agents for the treatment of lymphoma
patients. Cancers 2021;13:5535. DOI PubMed PMC
+
-
155. Scirocchi F, Scagnoli S, Botticelli A, et al. Immune effects of CDK4/6 inhibitors in patients with HR /HER2 metastatic breast
cancer: relief from immunosuppression is associated with clinical response. EBioMedicine 2022;79:104010. DOI PubMed PMC
156. Kohlhapp FJ, Haribhai D, Mathew R, et al. Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination
with immune checkpoint blockade. Cancer Discov 2021;11:68-79. DOI
157. Anandappa AJ, Wu CJ, Ott PA. Directing traffic: how to effectively drive T cells into tumors. Cancer Discov 2020;10:185-97. DOI
PubMed PMC
158. Wei T, Zhong W, Li Q. Role of heterogeneous regulatory T cells in the tumor microenvironment. Pharmacol Res 2020;153:104659.
DOI PubMed
159. Principe DR, Chiec L, Mohindra NA, Munshi HG. Regulatory T-cells as an emerging barrier to immune checkpoint inhibition in lung
cancer. Front Oncol 2021;11:684098. DOI PubMed PMC
160. Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval
decennial. Nat Rev Drug Discov 2022;21:509-28. DOI PubMed
161. Jameson-Lee M, Luke JJ. Ipilimumab combination dosing: less is more. Clin Cancer Res 2021;27:5153-5. DOI PubMed PMC
162. Di Giacomo AM, Lahn M, Eggermont AM, et al. The future of targeting cytotoxic T-lymphocyte-associated protein-4: is there a role?
Eur J Cancer 2023;198:113501. DOI